Welcome to our dedicated page for Nu Skin Enter SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nu Skin Enterprises, Inc. (NYSE: NUS) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its integrated beauty and wellness operations. These SEC filings cover the performance of the Nu Skin and Rhyz businesses, including revenue, margins, segment results and key metrics such as Customers, Paid Affiliates and Sales Leaders in the core Nu Skin business.
Among the most important filings for NUS are its annual reports on Form 10-K, which describe the company’s business model, risk factors, segment structure, accounting policies and long-term trends, and its quarterly reports on Form 10-Q, which update investors on interim financial performance and regional results. Nu Skin also uses Form 8-K to report material events, such as the release of quarterly and year-to-date financial results, including revenue, earnings per share, non-GAAP measures like constant-currency revenue change and adjusted EPS, and commentary on operating conditions.
In addition, investors can review proxy statements for information on governance and executive compensation, and Form 4 filings to track insider transactions by directors and officers. These documents help clarify how Nu Skin’s leadership and affiliate-driven model align with shareholder interests.
On this page, Stock Titan provides real-time access to Nu Skin’s latest SEC filings as they are posted to EDGAR, along with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-hundred-page 10-Ks or detailed 10-Qs, you can use these summaries to understand segment performance, changes in margins, updates on initiatives such as Prysm iO and regional expansion, and other material disclosures. Filings related to non-GAAP measures, restructuring and gains or losses from business sales are also highlighted so you can see how they affect reported results.
Nu Skin Enterprises is asking stockholders to vote at its May 28, 2026 annual meeting on four items: electing nine directors, an advisory vote on executive pay, approving an amended and restated 2024 Omnibus Incentive Plan, and ratifying PricewaterhouseCoopers LLP as auditor for 2026.
The company highlights strong governance practices, including a mostly independent board, separate Chair and CEO roles, a lead independent director, annual board/committee evaluations, and robust risk, cybersecurity and sustainability oversight. Executive pay is heavily performance-based: 2025 cash incentives paid at 21.9% of target after financial metrics came in below minimum levels, while some performance stock units paid out partly or not at all.
In 2025, Nu Skin generated $1.49 billion in revenue with core Nu Skin gross margin of 77.4%, and completed a $250 million sale of its Mavely business, using proceeds to reduce debt and fund innovation. CEO Ryan Napierski’s 2025 compensation was $5.97 million, largely in equity, and 97% of votes supported the prior say-on-pay proposal, which the board views as endorsement of its pay-for-performance design.
NU SKIN ENTERPRISES, INC. Chief Financial Officer Chelsea K. Lantz filed an initial Form 3 reporting her beneficial ownership in the company. The filing shows direct holdings of 42,100 shares of Class A Common Stock, establishing her reported equity position as an executive officer.
Nu Skin Enterprises entered into a new Second Amended and Restated Credit Agreement on March 27, 2026, establishing a $175 million term loan and a $75 million revolving credit facility, each with a five-year term. The term loan was fully drawn at closing and used to repay all amounts outstanding under the prior credit agreement, effectively refinancing the company’s main bank debt.
The revolving facility includes up to $10 million for swingline loans and up to $10 million for letters of credit. Loans bear interest at Term SOFR plus a spread starting at 1.75% or at a base rate plus a spread starting at 0.75%, with both spreads adjustable based on Nu Skin’s consolidated leverage ratio.
The facilities are guaranteed by certain material domestic subsidiaries and secured by liens on the capital stock of material subsidiaries. Key financial covenants require a consolidated leverage ratio not exceeding 2.25 to 1.00 and an interest coverage ratio of at least 3.00 to 1.00, alongside customary restrictions on additional debt, liens, dividends, acquisitions and asset sales.
Nu Skin Enterprises Inc: The Vanguard Group reports it beneficially owns 0 shares (0%) of Nu Skin common stock following an internal realignment. The filing states certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Nu Skin Enterprises announced that Executive Vice President and Chief Financial Officer James D. Thomas resigned on March 17, 2026 to pursue an outside opportunity. On March 18, 2026, the board appointed Vice President and Corporate Controller Chelsea K. Lantz as Interim CFO while a search for a permanent CFO, including internal and external candidates, is conducted.
Lantz, age 42, has been with Nu Skin since 2011 in various finance and audit roles and became Corporate Controller in 2023. As Interim CFO she will receive a $300,000 annual salary, a target incentive bonus equal to 35% of salary, and a $25,000 stipend for each quarter she serves in the interim role. The company states there are no family relationships or related-person transactions involving her and expects to enter into a standard indemnification agreement. A press release dated March 20, 2026 announces her appointment and highlights her role in cost-improvement efforts that contributed to a significant year-over-year EPS increase.
NU SKIN ENTERPRISES director Edwina D. Woodbury acquired additional shares through a plan-related dividend reinvestment. On 2026-03-11, she received 14 shares of Class A Common Stock at $7.31 per share under the company’s Deferred Compensation Plan. Following this automatic, non-open-market transaction, she directly holds 42,993 shares.
Keisel Justin S reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. executive Justin S. Keisel, EVP and President of Global Sales, received a grant of 47,059 shares of Class A Common Stock. The award was recorded at a price of $0.00 per share, indicating an equity grant rather than an open-market purchase. Following this grant, Keisel directly holds 160,170 shares of Nu Skin Class A Common Stock.
Nu Skin Enterprises Chief Product Officer Steven Keith Hatchett reported an equity award of 77,941 shares of Class A common stock on March 6, 2026. The shares were acquired as a grant with a reported price of $0.00 per share, indicating a non-cash award. Following this grant, Hatchett's directly held ownership increased to 260,818 shares of Nu Skin Class A common stock.
Nu Skin Enterprises executive Chayce David Clark received a large stock award that increases his direct ownership stake. On March 6, 2026, he was granted 138,971 shares of Nu Skin Class A Common Stock at no acquisition cost. After this grant, he directly owns 390,746 shares.